1 00:00:04,145 --> 00:00:08,445 Intro: Hello, and welcome to the Movement Prescription Podcast. This week, 2 00:00:08,545 --> 00:00:13,285 Intro: we have a slightly different episode where both Hussein, Susie, and I are on the podcast. 3 00:00:14,385 --> 00:00:18,465 Intro: Hussein recently has become a bit of an expert in GLP-1 agonists, 4 00:00:18,685 --> 00:00:21,985 Intro: and so Susie and I decided to interview him. 5 00:00:22,305 --> 00:00:26,885 Intro: It's quite a wide ranging episode where we initially talk about what they are, 6 00:00:27,205 --> 00:00:32,365 Intro: their licenses for use, their side effects and their effectiveness before importantly 7 00:00:32,365 --> 00:00:36,165 Intro: going on to talk about lifestyle and particularly physical activity. 8 00:00:36,725 --> 00:00:41,665 Intro: At the end Hussein has some real action points and calls to action whether you're 9 00:00:41,665 --> 00:00:45,905 Intro: a health professional, work in the physical activity sector or just someone 10 00:00:45,905 --> 00:00:49,285 Intro: that's really interested in their own health. We really hope you enjoy. 11 00:00:52,585 --> 00:00:54,065 Callum: Hey guys how's it going? 12 00:00:55,085 --> 00:00:56,245 Hussain: Very well thank you. 13 00:00:56,945 --> 00:00:57,525 Suzy: Hi, Callan. 14 00:00:57,845 --> 00:01:02,165 Callum: This is a slightly different episode today. And Hussein, if someone's tuning 15 00:01:02,165 --> 00:01:07,485 Callum: in for the first time, can you give us a quick introduction to you and what you do? 16 00:01:08,725 --> 00:01:16,465 Hussain: So my name's Hussein. I'm a GP based in the West Midlands, and I have an extended 17 00:01:16,465 --> 00:01:22,185 Hussain: role in lifestyle medicine with a number of different options sort of in a portfolio career. 18 00:01:22,185 --> 00:01:29,025 Hussain: I work at the Royal College of GPs alongside yourself as one of the Physical Activity Champions. 19 00:01:29,525 --> 00:01:32,905 Hussain: I also work at Parkrun as the Health Partnerships Lead. 20 00:01:33,605 --> 00:01:40,385 Hussain: And I'm the Lifestyle Medicine Course Lead at Red Whale, GP Update, as many of you will know. 21 00:01:40,565 --> 00:01:44,445 Hussain: So creating content there and also leading their obesity course. 22 00:01:45,425 --> 00:01:48,085 Callum: Great, thanks. And often on TV, don't forget that. 23 00:01:48,505 --> 00:01:49,725 Hussain: Well, every now and again. 24 00:01:49,825 --> 00:01:51,485 Callum: Good morning. Great Britain. 25 00:01:53,625 --> 00:01:58,905 Callum: So today i susie was gonna open with a great question which she posted me earlier 26 00:01:58,905 --> 00:02:02,625 Callum: susie before i steal your sandwiches i'm gonna let you you ask that question. 27 00:02:02,625 --> 00:02:06,725 Suzy: Hussein this is a this is an episode with a difference because obviously we're 28 00:02:06,725 --> 00:02:10,665 Suzy: entitling it the the glp ones and physical activity but why are we talking about 29 00:02:10,665 --> 00:02:14,765 Suzy: a medication on the movement prescription podcast that's. 30 00:02:14,765 --> 00:02:21,845 Hussain: A fantastic question. And I think its answer is quite complicated, 31 00:02:21,845 --> 00:02:23,505 Hussain: but I'll give you a simple one. 32 00:02:24,045 --> 00:02:30,205 Hussain: When we think about how GLP-1s are going to be used, physical activity has a 33 00:02:30,205 --> 00:02:32,605 Hussain: really important aspect to every part of that. 34 00:02:32,905 --> 00:02:37,205 Hussain: Not just how we should prepare patients before they start treatment, 35 00:02:38,711 --> 00:02:43,811 Hussain: Not only that the evidence shows that physical activity, in particular resistance 36 00:02:43,811 --> 00:02:47,491 Hussain: training during treatment, yields better results. 37 00:02:48,351 --> 00:02:53,451 Hussain: And I think most importantly, physical activity has been shown to be probably 38 00:02:53,451 --> 00:03:00,911 Hussain: the biggest lever that the patient can pull to prevent weight regain after stopping these injections. 39 00:03:01,091 --> 00:03:04,371 Hussain: And that's visibly important, not just for the patient so they don't go through 40 00:03:04,371 --> 00:03:09,471 Hussain: yo-yoing exercise of losing weight and the psychological trauma that that leads to. 41 00:03:09,791 --> 00:03:15,331 Hussain: But when we think about the cost of tizepatide on the NHS, which is one of the 42 00:03:15,331 --> 00:03:23,991 Hussain: leading GLP-1s and GIP injections, that's coming in at around £20,000 per quality adjusted life year. 43 00:03:24,111 --> 00:03:29,831 Hussain: And that's just right on the threshold for NICE in terms of what they would 44 00:03:29,831 --> 00:03:31,231 Hussain: class as being cost effective. 45 00:03:31,411 --> 00:03:36,611 Hussain: If we see significant weight regain on these injections, then we aren't going 46 00:03:36,611 --> 00:03:37,951 Hussain: to get that benefit, sadly. 47 00:03:39,491 --> 00:03:42,871 Callum: You're saying for people that are listening, and loads of people have heard 48 00:03:42,871 --> 00:03:47,911 Callum: about GLP-1 agonists, Wigovi, Tersepetide, some people might not have. 49 00:03:48,111 --> 00:03:52,871 Callum: And just could you give a really quick start of six about what GLP-1 agonists 50 00:03:52,871 --> 00:03:58,251 Callum: are, what they do, and maybe just briefly touch on the different names that 51 00:03:58,251 --> 00:03:59,231 Callum: we might have heard in the media. 52 00:03:59,891 --> 00:04:07,531 Hussain: So GLP-1 is a class of medications that you may have heard of recently, 53 00:04:07,531 --> 00:04:12,311 Hussain: but it's been around for a little while because we've been using it in type 2 diabetes. 54 00:04:13,171 --> 00:04:16,051 Hussain: Now, GLP-1 is naturally produced in the body. 55 00:04:16,271 --> 00:04:21,031 Hussain: It's actually produced in the small intestine, predominantly in the final part, 56 00:04:21,191 --> 00:04:23,551 Hussain: which is called the ileum, out of L-cells. 57 00:04:23,611 --> 00:04:27,551 Hussain: And when we eat meals, it responds to that, 58 00:04:28,031 --> 00:04:37,471 Hussain: releases GLP-1, glucose-like peptide, and it then acts on the brain to promote 59 00:04:37,471 --> 00:04:40,971 Hussain: the release of chemicals which make you feel full. 60 00:04:41,909 --> 00:04:46,609 Hussain: It's one of the short acting, um, hormones, if you think of it from that sense. 61 00:04:46,729 --> 00:04:51,269 Hussain: So it, it controls your hunger and satiety over short periods of time, 62 00:04:51,469 --> 00:04:56,609 Hussain: you know, over sort of minutes to hours, while you have longer acting, um, 63 00:04:57,089 --> 00:05:01,849 Hussain: hormones, things like insulin that, that will be controlling your hunger and 64 00:05:01,849 --> 00:05:05,249 Hussain: appetite levels over much longer periods of time. 65 00:05:05,389 --> 00:05:10,209 Hussain: So insulin, leptin, they generally are slow and your long-term control of appetite, 66 00:05:10,509 --> 00:05:15,489 Hussain: while things like peptide YY and GLP-1, these are all things that the body's 67 00:05:15,489 --> 00:05:18,849 Hussain: producing and just controlling it a more finite, shorter period of time. 68 00:05:19,329 --> 00:05:25,509 Hussain: Now, in terms of the agents that we've got, the first one that was predominantly 69 00:05:25,509 --> 00:05:29,529 Hussain: used in the UK was called Saxenda. 70 00:05:29,789 --> 00:05:32,309 Hussain: It's the trade name. The drug name is called loraglutide. 71 00:05:32,709 --> 00:05:35,709 Hussain: And that technology appraisal was released in 2020. 72 00:05:36,869 --> 00:05:41,169 Hussain: Before that, it was used for type 2 diabetes. But in how we work in the UK, 73 00:05:41,609 --> 00:05:45,729 Hussain: things have to be authorized for an indication. So for it to be used in weight 74 00:05:45,729 --> 00:05:49,229 Hussain: loss only rather than type 2 diabetes, that was 2020. 75 00:05:49,729 --> 00:05:54,849 Hussain: Then we had semaglutide, which trade name is called Wagovi. And that had its 76 00:05:54,849 --> 00:05:57,549 Hussain: technology appraisal issued in 2023. 77 00:05:59,162 --> 00:06:04,102 Hussain: And a lot of people, they know Wagovi, but the probably more well-known version 78 00:06:04,102 --> 00:06:06,222 Hussain: of semaglutide is a Zempic. 79 00:06:06,402 --> 00:06:12,062 Hussain: And now a Zempic is how it's authorized and licensed in type 2 diabetes. 80 00:06:12,422 --> 00:06:17,382 Hussain: So it's the same drug as Wagovi, but slightly different dose range because we 81 00:06:17,382 --> 00:06:21,822 Hussain: found that the majority of the weight loss benefits come in the higher doses. 82 00:06:22,142 --> 00:06:25,942 Hussain: So Wagovi is just think of it as a higher dose range to a Zempic. 83 00:06:25,942 --> 00:06:32,522 Hussain: And then the most recent one which was actually only authorized in december 2024. 84 00:06:33,322 --> 00:06:36,522 Hussain: Is to zapatide which is it 85 00:06:36,522 --> 00:06:42,742 Hussain: has a trade name manjaro and interestingly with to zapatide it's trade name 86 00:06:42,742 --> 00:06:46,822 Hussain: for type 2 diabetes and for weight loss is the same so just to sort of keep 87 00:06:46,822 --> 00:06:50,922 Hussain: the stop to buck the trend so to speak they've they've done it that way and 88 00:06:50,922 --> 00:06:53,742 Hussain: i think it's sensible because otherwise it just leads to a lot of confusion. 89 00:06:54,362 --> 00:07:00,162 Hussain: And that one's unique because unlike with semaglutide and loraglutide, 90 00:07:00,662 --> 00:07:04,022 Hussain: tezapatide has been authorized for both primary and secondary care. 91 00:07:04,442 --> 00:07:09,322 Hussain: So this is coming into primary care and that means a much wider audience of people. 92 00:07:09,442 --> 00:07:13,682 Hussain: And just to give you the impact that this is going to have, 2.8 million people 93 00:07:13,682 --> 00:07:16,162 Hussain: are eligible for tizepatide. 94 00:07:16,522 --> 00:07:23,862 Hussain: And it's estimated that one in five GP appointments will be related to either 95 00:07:23,862 --> 00:07:31,202 Hussain: starting titrating or managing in some way patients on specifically tizepatide. 96 00:07:31,362 --> 00:07:37,222 Hussain: So it's, it's both a challenge, but also an opportunity because if we know that physical 97 00:07:37,302 --> 00:07:43,782 Hussain: activity is a key element to ensure healthy weight loss and maintenance, 98 00:07:43,862 --> 00:07:50,122 Hussain: then this could well be the driver for change within primary care to get more 99 00:07:50,122 --> 00:07:51,902 Hussain: lifestyle, not just physical activity, 100 00:07:52,102 --> 00:07:54,542 Hussain: but more lifestyle medicine within primary care. 101 00:07:55,594 --> 00:08:01,534 Callum: A couple of things to just pick up on. I suppose, from my understanding, 102 00:08:01,734 --> 00:08:03,894 Callum: the research looks pretty good. 103 00:08:04,194 --> 00:08:09,754 Callum: The Wigovi, maybe 11% weight loss over 12 months is what they report, 104 00:08:10,014 --> 00:08:14,634 Callum: whereas the Majora terzepatide is 22% over 12 months. 105 00:08:14,634 --> 00:08:19,894 Hussain: So over 72 months. So over a longer period of time, so 72 months. 106 00:08:20,034 --> 00:08:23,494 Hussain: But although there's been no head-to-head trials between the two, 107 00:08:23,774 --> 00:08:27,834 Hussain: from what you can tell from looking at the different trials that have been done, 108 00:08:28,114 --> 00:08:30,754 Hussain: tisepatide does look more effective at weight loss. 109 00:08:30,854 --> 00:08:33,974 Hussain: And the key difference is tisepatide is a dual receptor. 110 00:08:34,194 --> 00:08:39,594 Hussain: It works both on GLP-1 and GIP, which is gastric inhibitory peptide. 111 00:08:40,154 --> 00:08:45,194 Hussain: Um, and there are a number of drugs down the line, which also work on either 112 00:08:45,194 --> 00:08:48,154 Hussain: dual or even triple because there's, there's something there's, 113 00:08:48,214 --> 00:08:52,194 Hussain: there's, there's a glucagon, um, receptor, which, which some, 114 00:08:52,194 --> 00:08:54,794 Hussain: um, drugs like retarutide, um, 115 00:08:55,134 --> 00:08:57,194 Hussain: and servutide is acting on. 116 00:08:57,314 --> 00:09:01,314 Hussain: So there's a lot of scope. This is not the, you know, we are by no means near 117 00:09:01,314 --> 00:09:02,234 Hussain: the middle of this story. 118 00:09:02,414 --> 00:09:06,154 Hussain: We're probably right in the first chapter of where this could potentially be going. 119 00:09:07,014 --> 00:09:13,874 Callum: And from my understanding, I've prescribed oral GLP-1 agonists for diabetes, 120 00:09:13,874 --> 00:09:19,154 Callum: but most of the stuff in the news is about weekly injectable forms because they're the most effective. 121 00:09:20,674 --> 00:09:25,074 Callum: And you talk about it being a big story. It is a huge story. It's all over the news. 122 00:09:25,994 --> 00:09:28,934 Callum: Susie, have you seen much of it? 123 00:09:29,054 --> 00:09:33,634 Callum: Have you know no doubt read the news what are your thoughts and and and experiences 124 00:09:33,634 --> 00:09:35,734 Callum: of kind of these drugs and and. 125 00:09:35,734 --> 00:09:38,734 Suzy: Yeah it's interesting isn't it because these are you know in in 126 00:09:38,734 --> 00:09:43,674 Suzy: the data they are fantastic class of drugs but they have got the the propensity 127 00:09:43,674 --> 00:09:48,154 Suzy: to maybe bankrupt the NHS if they're adopted as widely as they could be so I 128 00:09:48,154 --> 00:09:51,634 Suzy: suppose as general practitioners and you know with my various hats on you know 129 00:09:51,634 --> 00:09:56,914 Suzy: my lifestyle medicine hat on you know you begin to ask well if you're prescribing this, 130 00:09:56,994 --> 00:10:00,334 Suzy: is this a sticky plaster or are we dealing with the underlying pillars of health? 131 00:10:00,434 --> 00:10:03,554 Suzy: Are we dealing with the unhealthy food environment that we're living in? 132 00:10:03,654 --> 00:10:07,954 Suzy: Are we dealing with the environment that leads us to be sedentary, et cetera? 133 00:10:08,194 --> 00:10:13,374 Suzy: With my diabetes roll hat on, these are fantastic drugs for diabetes and I don't 134 00:10:13,374 --> 00:10:15,314 Suzy: think we should be, I think we need to, 135 00:10:17,281 --> 00:10:19,741 Suzy: is there enough to go around for the people who need it the most? 136 00:10:19,981 --> 00:10:22,481 Suzy: You know, forever talking about the people who need things the most, 137 00:10:22,621 --> 00:10:25,481 Suzy: whether that's lifestyle interventions or indeed medication. 138 00:10:27,541 --> 00:10:31,861 Suzy: We're aware of people getting them online from online pharmacies and completely 139 00:10:31,861 --> 00:10:33,921 Suzy: inappropriately getting them from online pharmacies. 140 00:10:34,041 --> 00:10:37,921 Suzy: So there's an overwhelming amount of information. It's quite difficult to focus our thoughts on this. 141 00:10:38,081 --> 00:10:42,681 Suzy: Have I prescribed much in the way of injectables only within patients who've 142 00:10:42,681 --> 00:10:46,441 Suzy: been started the injectables by the diabetes team. 143 00:10:46,581 --> 00:10:50,761 Suzy: But I'm fully aware with my other hat on, my LMC hat on, the medical politics 144 00:10:50,761 --> 00:10:55,121 Suzy: side of, you know, GPs are worried about the workload that is no doubt coming 145 00:10:55,121 --> 00:10:57,981 Suzy: their way, which will be slightly different in Scotland to what's coming your 146 00:10:57,981 --> 00:11:01,181 Suzy: way, Hussein, in England, I think, just with the different rules. 147 00:11:01,341 --> 00:11:03,401 Suzy: But, you know, it can feel overwhelming. 148 00:11:03,821 --> 00:11:08,281 Suzy: There are so many different types of GLP-1s and combinations that it can feel 149 00:11:08,281 --> 00:11:11,721 Suzy: very confusing. That's to use your word there, Hussein. 150 00:11:11,921 --> 00:11:18,101 Suzy: So I, you know, I have various views and I'm looking forward to learning from 151 00:11:18,101 --> 00:11:21,461 Suzy: all the work that you've done, Hussein, just helping to clarify and, 152 00:11:22,121 --> 00:11:24,041 Suzy: you know, what is within our power? 153 00:11:24,121 --> 00:11:27,241 Suzy: Because a lot of these prescribing decisions come from on high, don't they? 154 00:11:27,601 --> 00:11:31,401 Suzy: You know, once those decisions have been made, what is within our power? 155 00:11:31,501 --> 00:11:33,221 Suzy: How can we get the best out of these medications? 156 00:11:34,441 --> 00:11:38,161 Callum: For listeners, Susie not only gave an incredibly eloquent response, 157 00:11:38,401 --> 00:11:43,321 Callum: but she's also cuddling a 12-week-old puppy who is trying to bite her. 158 00:11:43,541 --> 00:11:47,221 Callum: And it's a masterclass in multitasking, isn't it, Hussain? 159 00:11:47,741 --> 00:11:52,981 Hussain: Absolutely. I was so thrown by that. No, I'm joking. I heard the question. It was fantastic. 160 00:11:54,081 --> 00:11:56,481 Hussain: Does it fix the underlying issues? No. 161 00:11:57,821 --> 00:12:02,301 Hussain: And I do fear that if it's not used as a tool, 162 00:12:03,801 --> 00:12:10,941 Hussain: then we will just exacerbate a lot of the kind of inherent issues as to why, unfortunately, 163 00:12:12,081 --> 00:12:17,661 Hussain: 70%, well, just under 70% of men and 60% of women are unfortunately overweight 164 00:12:17,661 --> 00:12:21,021 Hussain: and obese, and they're living with that. And so, 165 00:12:22,042 --> 00:12:28,282 Hussain: What we should think of it is not as the answer, but as a tool to support weight 166 00:12:28,282 --> 00:12:33,282 Hussain: loss, because we know physiologically, weight loss is extremely challenging. 167 00:12:33,782 --> 00:12:37,602 Hussain: Forget about the environment element that they're also having to combat and 168 00:12:37,602 --> 00:12:39,382 Hussain: the reason why the weight gain has happened. 169 00:12:39,522 --> 00:12:44,242 Hussain: It's really hard to achieve. So if we can utilize these injections, but it has to be done. 170 00:12:46,042 --> 00:12:49,602 Hussain: Alongside lifestyle support, not just nutrition and physical activity, 171 00:12:49,602 --> 00:12:54,802 Hussain: but beyond that in terms of how do we try to support the kind of the holistic 172 00:12:54,802 --> 00:12:58,862 Hussain: approach of both community elements, the stress that may be going on, 173 00:12:59,022 --> 00:13:00,242 Hussain: whether it be work, family, 174 00:13:00,422 --> 00:13:05,122 Hussain: how can we support patients in a long-term, in-depth way? 175 00:13:05,242 --> 00:13:10,082 Hussain: Because if all they're going to get is GLP-1, then I can assure you they will 176 00:13:10,082 --> 00:13:12,582 Hussain: lose weight, but then they will regain the weight. 177 00:13:13,122 --> 00:13:17,742 Hussain: And they are going to be either having to take GLP-1 injections for the rest 178 00:13:17,742 --> 00:13:22,642 Hussain: of their lives, or they're going to be aggressively yo-yoing in weight up and down. 179 00:13:22,822 --> 00:13:25,662 Hussain: And that, that's, I think will be a massive shame. 180 00:13:26,322 --> 00:13:32,422 Hussain: But I do fear that in terms of the rollout, in sort of the hope for scalability. 181 00:13:33,682 --> 00:13:35,902 Hussain: That we will see corners being cut. 182 00:13:36,102 --> 00:13:40,122 Hussain: And when corners are being cut, you will not lead to the long-term benefit that 183 00:13:40,122 --> 00:13:42,182 Hussain: you could potentially extract from this. 184 00:13:42,302 --> 00:13:46,202 Hussain: And you can see it in studies. There was one study that looked at a group of 185 00:13:46,202 --> 00:13:52,222 Hussain: patients, all had a year's worth of loraglutide, so that version of the GLP-1. 186 00:13:52,502 --> 00:13:56,302 Hussain: Now, one group had no physical activity support. 187 00:13:56,642 --> 00:14:01,302 Hussain: The other group had physical activity support. And it was in the sort of realm 188 00:14:01,302 --> 00:14:06,982 Hussain: of two sessions a week, half an hour, predominantly strength resistance training. 189 00:14:07,422 --> 00:14:12,962 Hussain: Now, when you looked at a year after stopping loraglutide. 190 00:14:13,672 --> 00:14:17,592 Hussain: The group that had just the GLP-1, no physical activity during that year, 191 00:14:17,852 --> 00:14:21,112 Hussain: had gained six kilograms on average. 192 00:14:21,632 --> 00:14:26,052 Hussain: But the group that had physical activity during that year, but not during the 193 00:14:26,052 --> 00:14:29,092 Hussain: year once they stopped it, they were left to their own devices after that. 194 00:14:29,532 --> 00:14:33,232 Hussain: They only gained two and a half kilograms. So that's a big difference. 195 00:14:33,452 --> 00:14:36,352 Hussain: And when you're thinking about the two and a half to six, when you then extrapolate 196 00:14:36,352 --> 00:14:42,632 Hussain: that across the population, that's many, many pounds. and that's also obviously 197 00:14:42,632 --> 00:14:44,472 Hussain: an improvement to their health as well. 198 00:14:44,612 --> 00:14:49,012 Hussain: So I think on many different fronts, we need to be careful not to rush these 199 00:14:49,012 --> 00:14:53,692 Hussain: things out and instead focus on how do we produce the wraparound support that's 200 00:14:53,692 --> 00:14:59,732 Hussain: necessary to make sure that patients have now an option to support them in healthy 201 00:14:59,732 --> 00:15:01,352 Hussain: weight loss rather than, 202 00:15:01,792 --> 00:15:05,412 Hussain: for example, you see the headlines of take GLP-1s to get people back to work. 203 00:15:05,632 --> 00:15:11,452 Hussain: And it's just such an over-reduction of the complexity of what an illness like 204 00:15:11,452 --> 00:15:17,112 Hussain: obesity is to think that somehow if you inject people, they'll be more likely to work. 205 00:15:17,292 --> 00:15:19,192 Hussain: There's so many other barriers that prevent that. 206 00:15:20,012 --> 00:15:24,072 Hussain: But I think it's really important that we consider that and we consider the whole package. 207 00:15:25,252 --> 00:15:29,512 Callum: Hussain, I really want to pick your brains from all the work you've done on 208 00:15:29,512 --> 00:15:31,512 Callum: kind of what the lifestyle and the physical activity look like. 209 00:15:31,512 --> 00:15:36,772 Callum: But before that, you mentioned two kind of really scary statistics earlier on, 210 00:15:36,872 --> 00:15:41,552 Callum: which is that 2.8 million people in the UK will be eligible and that it will 211 00:15:41,552 --> 00:15:45,192 Callum: account for 20% of all GP appointments in 12 years' time when it's fully rolled out. 212 00:15:45,792 --> 00:15:50,732 Callum: And that's based on the NICE guidance that was released in, was it December, 213 00:15:50,872 --> 00:15:54,632 Callum: which talked about everyone that's above a BMI of 35 will be eligible? 214 00:15:54,632 --> 00:15:57,652 Hussain: Yeah so that was specifically the technology the 215 00:15:57,652 --> 00:16:02,772 Hussain: nice technology appraisal for to zepatide because unlike the other glp ones 216 00:16:02,772 --> 00:16:06,972 Hussain: in the past to zepatide will be open in terms of where it can be prescribed 217 00:16:06,972 --> 00:16:10,752 Hussain: prescribed it doesn't need to be in specialist services yeah it will be open 218 00:16:10,752 --> 00:16:16,052 Hussain: to be described across and in the nice committee kind of guidance notes, 219 00:16:16,942 --> 00:16:23,082 Hussain: They explained that obesity is a chronic, long-term condition that affects many 220 00:16:23,082 --> 00:16:29,022 Hussain: people and therefore needs to be accessible, treatment needs to be accessible 221 00:16:29,022 --> 00:16:30,582 Hussain: in a wide range of places. 222 00:16:30,582 --> 00:16:36,202 Hussain: If we expect the huge proportion of our population to be going through specialist 223 00:16:36,202 --> 00:16:38,442 Hussain: weight management services, it's never going to happen. 224 00:16:38,662 --> 00:16:42,002 Hussain: Do you know what I mean? It's never going to, they're already inundated with huge wait lists. 225 00:16:42,282 --> 00:16:44,462 Hussain: For example, what's your wait list up in Scotland? And mine, 226 00:16:44,602 --> 00:16:46,042 Hussain: it's about two to three years. 227 00:16:46,642 --> 00:16:51,982 Callum: Yeah, the wait list is massive. But I think, I agree, we need to know about this. 228 00:16:52,102 --> 00:16:57,442 Callum: It's coming our way in like a tidal wave, isn't it? But also 20% of new appointments 229 00:16:57,442 --> 00:16:59,762 Callum: that just, where does that come? 230 00:16:59,862 --> 00:17:03,822 Callum: We're in a system that is bursting at the seams anyway. 231 00:17:04,022 --> 00:17:07,722 Callum: I think those statistics will scare a lot of people, I'm sure. 232 00:17:08,242 --> 00:17:10,502 Callum: And we need the systems, as you mentioned, in place. 233 00:17:11,202 --> 00:17:15,942 Hussain: Exactly. And currently there's a trial called the Surmount Real trial, 234 00:17:16,042 --> 00:17:20,742 Hussain: which is based in Manchester, in primary care, where they're assessing just 235 00:17:20,742 --> 00:17:22,242 Hussain: that, you know, how can it be delivered? 236 00:17:23,402 --> 00:17:28,642 Hussain: More than likely, it's going to be outside of your traditional kind of clinic sessions. 237 00:17:29,122 --> 00:17:35,502 Hussain: And also, who's delivering it? Because I think from what most evidence shows, 238 00:17:35,682 --> 00:17:40,522 Hussain: it doesn't need to be clinician-led all the time. I think there obviously needs 239 00:17:40,522 --> 00:17:41,602 Hussain: to be a prescriber there. 240 00:17:41,922 --> 00:17:46,502 Hussain: But that wraparound support, that could be group consultations for example. 241 00:17:47,922 --> 00:17:52,842 Hussain: The physical activity groups that could be linking in with local physical activity 242 00:17:52,842 --> 00:17:58,122 Hussain: partners into the current referral pathways that they could have dedicated ones 243 00:17:58,122 --> 00:18:00,622 Hussain: for these kind of presets. 244 00:18:00,842 --> 00:18:05,522 Hussain: So that scalability is going to be really important. Now, the worry is that 245 00:18:05,522 --> 00:18:07,902 Hussain: they're going to go for kind of the minimum effective option, 246 00:18:08,062 --> 00:18:10,162 Hussain: which I think isn't right in this case. 247 00:18:10,322 --> 00:18:16,222 Hussain: I think obesity is too complicated and too important a societal issue that we 248 00:18:16,222 --> 00:18:18,602 Hussain: should go for the minimal effective dose. 249 00:18:19,162 --> 00:18:27,242 Hussain: And my hope is that what we will see is potentially a shift in how even primary care is delivered. 250 00:18:27,462 --> 00:18:32,722 Hussain: So we start to understand that 10 minutes or 15 minutes or even 20 minutes is 251 00:18:32,722 --> 00:18:35,462 Hussain: not an enough time for long-term conditions. 252 00:18:35,642 --> 00:18:42,102 Hussain: And instead, we need an approach which is based on intensive support and then 253 00:18:42,102 --> 00:18:47,022 Hussain: a titration down where, for example, they come in and they have maybe a 12-week, 254 00:18:47,222 --> 00:18:51,662 Hussain: once a week group consultation with support from a dietician and a health coach. 255 00:18:51,882 --> 00:18:56,322 Hussain: And then, yes, they have the prescriber who's doing the GLP-1 maintenance and 256 00:18:56,322 --> 00:18:59,322 Hussain: ensuring that is done correctly and safely. 257 00:18:59,522 --> 00:19:03,542 Hussain: And then slowly, then that gets weaned off. But they have support for one, 258 00:19:03,742 --> 00:19:04,902 Hussain: two, maybe even three years. 259 00:19:05,142 --> 00:19:08,782 Hussain: That support may suddenly turn into 12 weekly e-check-ins, etc.. 260 00:19:09,811 --> 00:19:12,931 Hussain: But I think that's what's necessary. And, you know, Susie made a point of that, 261 00:19:13,031 --> 00:19:15,671 Hussain: you know, people are going online, filling out an online form, 262 00:19:16,051 --> 00:19:19,311 Hussain: getting a prescription from the pharmacy, and they're not speaking to anyone. 263 00:19:19,831 --> 00:19:24,911 Hussain: You know, they're not seeing anyone. In fact, today, the General Pharmaceutical 264 00:19:24,911 --> 00:19:28,971 Hussain: Council actually issued guidance saying that that can't happen. 265 00:19:29,071 --> 00:19:31,791 Hussain: You know, you have to at least, you know, touch base with the patient. 266 00:19:31,951 --> 00:19:36,611 Hussain: The patient has to at least have a port of call in terms of contacting someone 267 00:19:36,611 --> 00:19:39,911 Hussain: if they have issues, et cetera. So that's been tightened up a little bit now, 268 00:19:40,031 --> 00:19:42,091 Hussain: but it's still, that's not gold standard care. 269 00:19:42,271 --> 00:19:44,991 Hussain: I wouldn't even call that kind of like bronze standard care, 270 00:19:45,031 --> 00:19:48,891 Hussain: what a lot of people are getting. And the vast majority are getting it that way. 271 00:19:49,271 --> 00:19:53,651 Hussain: In terms of accessibility to these injections, because for a long time we've 272 00:19:53,651 --> 00:19:54,651 Hussain: had national shortages. 273 00:19:55,331 --> 00:20:03,291 Hussain: And that's because the drug company just did not predict the level of response to these medications. 274 00:20:03,291 --> 00:20:08,571 Hussain: And so Nova Nordisk, which does like Wagovi and Sexenda, like it takes a long 275 00:20:08,571 --> 00:20:11,991 Hussain: time to increase production and for that to actually filter through. 276 00:20:12,371 --> 00:20:16,971 Hussain: Now, Eli Lilly, which make Tizepatide, like they've kind of had a bit more head 277 00:20:16,971 --> 00:20:19,731 Hussain: start in terms of they've seen what the market is like. 278 00:20:19,911 --> 00:20:23,051 Hussain: And so there isn't any stock issues currently for Tizepatide. 279 00:20:23,171 --> 00:20:26,791 Hussain: So I can see a future where stock isn't going to be a problem anymore. 280 00:20:26,811 --> 00:20:31,211 Hussain: It's going to be about actually delivering this because it's estimated that 281 00:20:31,211 --> 00:20:35,591 Hussain: through the NHS, even in primary care, it will take 12 years to get through 282 00:20:35,591 --> 00:20:36,831 Hussain: everybody that's eligible. 283 00:20:38,931 --> 00:20:44,911 Callum: I'm stuck for words. There's so much to process. There's a couple of things 284 00:20:44,911 --> 00:20:47,371 Callum: I suppose that I wanted to touch on. 285 00:20:47,731 --> 00:20:50,511 Callum: And one Susie and I actually have talked about. 286 00:20:51,371 --> 00:20:55,611 Callum: We talked a bit about what physical activity is needed. 287 00:20:56,091 --> 00:21:04,371 Callum: And I think Susie had said previously that are we at risk of switching one kind 288 00:21:04,371 --> 00:21:09,731 Callum: of issue of obesity with another, which is sarcopenia and muscle loss? 289 00:21:10,654 --> 00:21:15,554 Callum: And so, yeah, maybe you could kind of tell us a bit about the evidence behind that, Hussein. 290 00:21:16,274 --> 00:21:22,254 Callum: And then the other thing is, you know, we've got quite a few patients that have a similar issue. 291 00:21:22,394 --> 00:21:25,414 Callum: The pharmacy issues, they're kind of prescribed online, no follow-up. 292 00:21:25,774 --> 00:21:31,274 Callum: And they have come in with side effects. And I think the side effects aren't 293 00:21:31,274 --> 00:21:32,954 Callum: well publicized as far as I'm aware. 294 00:21:33,594 --> 00:21:37,014 Callum: And so I think it would be really helpful possibly from a listener's perspective 295 00:21:37,014 --> 00:21:41,194 Callum: to know what those side effects of the medication are. So maybe start with the 296 00:21:41,194 --> 00:21:46,134 Callum: side effects and then tell us a bit about, you know, sarcopenia and resistance training. 297 00:21:46,854 --> 00:21:49,894 Hussain: Yeah, no, very good question. So starting off with the side effects, 298 00:21:50,374 --> 00:21:53,094 Hussain: they will never ever be well sort of published. 299 00:21:53,234 --> 00:21:56,314 Hussain: I don't think it's something that anyone wants to advertise, but they are there. 300 00:21:56,434 --> 00:21:59,794 Hussain: And I'd say they're higher than what you'd normally get in most of the medications 301 00:21:59,794 --> 00:22:03,314 Hussain: we prescribe. And you can tell that because of the adherence, 302 00:22:03,794 --> 00:22:05,174 Hussain: like long-term adherence. 303 00:22:05,374 --> 00:22:08,374 Hussain: So over 12 months is pretty low. It's like under 10%. 304 00:22:08,374 --> 00:22:12,034 Hussain: So that's telling you that, you know, this is something that people are struggling 305 00:22:12,034 --> 00:22:16,814 Hussain: to maintain on, but there's lots of, and it's interesting, actually, 306 00:22:16,934 --> 00:22:20,434 Hussain: there's lots of lifestyle factors that improve the side effect profile. 307 00:22:20,594 --> 00:22:25,494 Hussain: And often it's that issue of, because they haven't got the lifestyle factors 308 00:22:25,494 --> 00:22:28,314 Hussain: quite aligned, it makes it much harder to tolerate. 309 00:22:28,634 --> 00:22:32,294 Hussain: So the most common ones are all gastrointestinal. We're talking about nausea, 310 00:22:32,634 --> 00:22:37,074 Hussain: diarrhea, vomiting, abdominal pain, constipation as well. 311 00:22:37,074 --> 00:22:40,254 Hussain: And then also there's injection site reactions these 312 00:22:40,254 --> 00:22:42,914 Hussain: are things that you inject yourself you put it into the 313 00:22:42,914 --> 00:22:45,714 Hussain: subcutaneous tissue so you're advised to 314 00:22:45,714 --> 00:22:48,534 Hussain: rotate around four different spots around the body 315 00:22:48,534 --> 00:22:53,754 Hussain: but you can get reactions where the skin will become inflamed etc now there 316 00:22:53,754 --> 00:22:58,574 Hussain: are rare but more serious side effects and it's hard to know exactly the kind 317 00:22:58,574 --> 00:23:04,374 Hussain: of incidence of these because in you can get data from the trials but generally 318 00:23:04,374 --> 00:23:08,354 Hussain: when you look in real life data you tend to get more of these than you get in the trials. 319 00:23:08,674 --> 00:23:12,434 Hussain: And we're talking about things like increased suicidality. 320 00:23:13,194 --> 00:23:19,254 Hussain: So there's been about 150 case reports of increased suicide risk and self harm behavior. 321 00:23:19,634 --> 00:23:24,454 Hussain: And weirdly, or maybe even not weirdly, but this is seen in bariatric surgery as well. 322 00:23:24,594 --> 00:23:30,834 Hussain: So we don't know if this is a symptom of rapid weight loss or a symptom specifically 323 00:23:30,834 --> 00:23:35,534 Hussain: of, you know, separate, that's bariatric surgery and GLP-1 medications do it, 324 00:23:35,694 --> 00:23:38,994 Hussain: but there seems to be a, um, element between the two. 325 00:23:39,534 --> 00:23:43,934 Hussain: And the other one, which is thyroid cancer. 326 00:23:44,234 --> 00:23:50,034 Hussain: So both papillary and medullary cancer, thyroid cancer is more common or at 327 00:23:50,034 --> 00:23:53,994 Hussain: least I'd say associated because there's no causation that's been proven through 328 00:23:53,994 --> 00:23:56,014 Hussain: here, but there's an association. So there was. 329 00:23:58,517 --> 00:24:04,117 Hussain: In patients between one to three years of use of GLP-1s, there was a 58% increase 330 00:24:04,117 --> 00:24:07,717 Hussain: in terms of relative risk, sorry, absolute risk. 331 00:24:08,317 --> 00:24:11,957 Hussain: But when you need to bear that in mind, that sort of 58%, so that is, 332 00:24:12,097 --> 00:24:13,517 Hussain: yeah, quite a chunk increase. 333 00:24:13,937 --> 00:24:19,297 Hussain: But thyroid cancer is actually really rare. So you're making a really rare cancer 334 00:24:19,297 --> 00:24:21,077 Hussain: into something that's slightly less rare. 335 00:24:22,037 --> 00:24:28,177 Hussain: So when you look at a population, we probably aren't overly concerned by that. 336 00:24:28,757 --> 00:24:32,257 Hussain: And because they're such small numbers, any increase will always look like a 337 00:24:32,257 --> 00:24:35,577 Hussain: huge percentage when it probably isn't such. 338 00:24:35,977 --> 00:24:40,917 Hussain: Now, in terms of how we can sort of minimize these side effects, 339 00:24:41,057 --> 00:24:46,177 Hussain: we know that patients that have higher fiber and water in their diet tend to get less constipation. 340 00:24:47,057 --> 00:24:53,577 Hussain: Those that have lower saturated fats and smaller portion sizes have less nausea. 341 00:24:53,577 --> 00:24:56,597 Hussain: Um if they have a diet 342 00:24:56,597 --> 00:25:00,397 Hussain: that's high in vitamin a d e k 343 00:25:00,397 --> 00:25:03,117 Hussain: and beta carotene you tend to see less of 344 00:25:03,117 --> 00:25:06,837 Hussain: the kind of nutritional deficiencies that you may get so it 345 00:25:06,837 --> 00:25:12,837 Hussain: just really kind of really sells the importance that when someone's on a reduced 346 00:25:12,837 --> 00:25:16,117 Hussain: calorie diet which will naturally happen when your appetite's been significantly 347 00:25:16,117 --> 00:25:20,557 Hussain: suppressed the quality becomes even more important okay Because if you're eating 348 00:25:20,557 --> 00:25:23,457 Hussain: less of not such good quality food, 349 00:25:23,457 --> 00:25:27,117 Hussain: that's going to have a much bigger impact in terms of the lack of fiber, 350 00:25:27,317 --> 00:25:28,597 Hussain: the lack of nutritional elements. 351 00:25:28,837 --> 00:25:33,417 Hussain: So patients need to be supported with this, not just when they're on the GLP 352 00:25:33,417 --> 00:25:37,437 Hussain: ones, but beforehand, you know, it needs to be kind of like a phased approach 353 00:25:37,437 --> 00:25:40,597 Hussain: where you bring in these elements of nutrition and physical activity, 354 00:25:40,597 --> 00:25:43,597 Hussain: and then the medication gets inserted at the right point. 355 00:25:43,897 --> 00:25:48,277 Hussain: Does that make sense? Now, exactly what point that will be, that will need to 356 00:25:48,277 --> 00:25:52,857 Hussain: be studied and to decide what is the most sensible point to start a GLP-1. 357 00:25:53,317 --> 00:25:57,497 Hussain: In reality, what's happening is people are just going onto the GLP-1 and then 358 00:25:57,497 --> 00:26:01,537 Hussain: they're having to try and work this all out afterwards with minimal support. 359 00:26:02,397 --> 00:26:07,457 Hussain: And that's not going to lead to long-term benefits. Now, you asked about the 360 00:26:07,457 --> 00:26:11,417 Hussain: sarcopenia question. So that's sort of losing muscle mass. 361 00:26:11,677 --> 00:26:19,917 Hussain: And that is an interesting question that He's got people on both sides of the debate. Okay. So, okay. 362 00:26:20,403 --> 00:26:27,863 Hussain: Now, firstly, agreement as to how common sarcopenia is within obese patients 363 00:26:27,863 --> 00:26:31,903 Hussain: is not clear because there's wide range. 364 00:26:32,143 --> 00:26:35,223 Hussain: From one study to the other, you can see different proportion of patients that 365 00:26:35,223 --> 00:26:38,203 Hussain: are suffering with sarcopenia while obese. 366 00:26:38,323 --> 00:26:41,583 Hussain: And that can sometimes sound quite counterintuitive because you think, 367 00:26:41,703 --> 00:26:44,063 Hussain: well, surely they've got significant muscle mass. 368 00:26:44,163 --> 00:26:47,563 Hussain: That's not the problem, but no, you can get sarcogenic obesity, 369 00:26:47,563 --> 00:26:50,843 Hussain: but that's generally seen in older populations. 370 00:26:51,343 --> 00:26:55,143 Hussain: Okay. So older populations that are less active, they generally have lower muscle 371 00:26:55,143 --> 00:26:57,963 Hussain: mass and higher body fat ratio. 372 00:26:58,303 --> 00:27:01,343 Hussain: And that's one of the reasons why NICE tell us if they're over 65, 373 00:27:01,363 --> 00:27:03,303 Hussain: you shouldn't be using a BMI. 374 00:27:03,383 --> 00:27:08,483 Hussain: You should be using a waist to height ratio to try to pick that up because the 375 00:27:08,483 --> 00:27:13,583 Hussain: BMI may be great, but actually it's great because they've lost like eight kilos 376 00:27:13,583 --> 00:27:16,963 Hussain: of of muscle and gained eight kilos of fat. 377 00:27:17,163 --> 00:27:22,103 Hussain: So it's really mindful of that. Now for the majority of younger patients that are obese. 378 00:27:22,963 --> 00:27:26,843 Hussain: Sarcopenia is relatively rare because if you're being active and getting on 379 00:27:26,843 --> 00:27:30,443 Hussain: with your day, you're actually probably got slightly more muscle mass than most 380 00:27:30,443 --> 00:27:35,603 Hussain: because you're literally having to move and bear higher levels of weight. 381 00:27:36,083 --> 00:27:42,863 Hussain: Now, GLP-1s don't uniquely reduce muscle mass when you have the weight loss process. 382 00:27:42,863 --> 00:27:46,843 Hussain: This is something that happens with any rapid weight loss. You will have about 383 00:27:46,843 --> 00:27:51,323 Hussain: 25 to 40% muscle mass loss. Okay. 384 00:27:51,603 --> 00:27:56,263 Hussain: And that isn't just purely just muscle, but we call it fat free mass. 385 00:27:56,403 --> 00:28:00,663 Hussain: So that's muscle, but it's also like body fluids, organs, tissues. 386 00:28:01,043 --> 00:28:05,163 Hussain: You know, there's lots of things that contribute into that fat free mass. 387 00:28:05,383 --> 00:28:08,723 Hussain: Now, the majority of it is likely going to be skeletal muscle. 388 00:28:09,763 --> 00:28:15,023 Hussain: But at the moment, no studies have looked at breaking the fat-free mass down 389 00:28:15,023 --> 00:28:18,683 Hussain: because in terms of what you'd need to use as a modality, you'd have to use 390 00:28:18,683 --> 00:28:22,803 Hussain: MRI to work that out because DEXA just tells you kind of what's bone. 391 00:28:23,003 --> 00:28:27,563 Hussain: It tells you what's fat, but then the rest is kind of like, it just lumps it in one big group. 392 00:28:27,683 --> 00:28:32,323 Hussain: So DEXA is, is, is very easy to do on a trial setting with lots of patients. 393 00:28:32,823 --> 00:28:36,783 Hussain: MRI is a lot more expensive and arduous. So hopefully there'll be studies that 394 00:28:36,783 --> 00:28:38,743 Hussain: explore that so we really get an idea. 395 00:28:39,263 --> 00:28:43,283 Hussain: But what we find is that the more rapid the weight loss is, the more likely 396 00:28:43,283 --> 00:28:46,943 Hussain: you are to see a drop in muscle mass. 397 00:28:47,083 --> 00:28:54,123 Hussain: But interestingly, the GLP-1s all have different levels to which we see this. 398 00:28:54,263 --> 00:28:56,983 Hussain: Now, not in head-to-head trials, but looking at separate trials. 399 00:28:57,901 --> 00:29:03,841 Hussain: Um, tizepatide seems to be better at preserving the muscle mass loss compared 400 00:29:03,841 --> 00:29:06,501 Hussain: to semaglutide, which is the Zempic-Wagovie. 401 00:29:06,801 --> 00:29:11,321 Hussain: For example, we saw with the Zempic and sort of the semaglutide trial, 402 00:29:11,481 --> 00:29:17,381 Hussain: that was 39% fat free mass lost, while with tizepatide, it was 25%. 403 00:29:17,381 --> 00:29:18,701 Hussain: So a significant difference. 404 00:29:18,941 --> 00:29:23,761 Hussain: Now, in terms of how do we minimize the muscle mass loss, we come back to lifestyle. 405 00:29:23,901 --> 00:29:26,441 Hussain: Okay. The number one thing is physical activity. 406 00:29:26,861 --> 00:29:33,321 Hussain: Resistance training will very much help to prevent that muscle mass loss to as a severe level. 407 00:29:33,561 --> 00:29:37,561 Hussain: And then the other bit is increased protein intake. So if you've had increased 408 00:29:37,561 --> 00:29:40,781 Hussain: protein intake, it's not really the timing during the day. 409 00:29:40,921 --> 00:29:46,641 Hussain: It tends to be the total amount that's being consumed in the day that also preserves muscle mass. 410 00:29:46,721 --> 00:29:49,881 Hussain: And it's all because of the signaling that happens when your body absorbs a 411 00:29:49,881 --> 00:29:54,521 Hussain: higher dose of protein. It's all signals to the muscles to try to regenerate 412 00:29:54,521 --> 00:29:55,941 Hussain: and to increase structure. 413 00:29:56,201 --> 00:30:03,101 Hussain: So generally, overall, what we're seeing, we want to have a slower approach to the weight loss. 414 00:30:03,221 --> 00:30:06,641 Hussain: So using lower doses for a bit longer rather than higher doses for shorter. 415 00:30:06,841 --> 00:30:11,861 Hussain: We want a higher protein intake and we want to encourage them to include resistance 416 00:30:11,861 --> 00:30:13,521 Hussain: training that doesn't have to be in the gym. 417 00:30:13,681 --> 00:30:17,081 Hussain: You know, that could be home workouts that can be getting them to do some gardening, 418 00:30:17,081 --> 00:30:21,941 Hussain: whatever it is we just need to test the muscles and try to have a more old body 419 00:30:21,941 --> 00:30:26,081 Hussain: approach to preserve your muscle mass thanks. 420 00:30:26,081 --> 00:30:28,841 Callum: Usain that was a big answer to a number. 421 00:30:28,841 --> 00:30:31,081 Hussain: Of questions that I just splurted. 422 00:30:31,081 --> 00:30:35,061 Callum: Out so that was great Susie have you got any questions. 423 00:30:35,061 --> 00:30:40,481 Suzy: No I was just furiously making notes there because I can almost visualize like 424 00:30:40,481 --> 00:30:44,201 Suzy: a one-page summary of the lifestyle interventions that we need to go alongside 425 00:30:44,201 --> 00:30:47,581 Suzy: this one tool and what I would call the obesity jigsaw. 426 00:30:47,741 --> 00:30:50,841 Suzy: So I tend to do this in mental health. I talk about the mental health jigsaw. 427 00:30:51,361 --> 00:30:54,421 Suzy: Um, and I can almost see the one page summary now. 428 00:30:54,921 --> 00:30:57,741 Hussain: And that's what we've done at the Red Whale, um, lifestyle medicine course that 429 00:30:57,741 --> 00:31:01,661 Hussain: we've created like a visual gem, which sort of brings it all together so that 430 00:31:01,661 --> 00:31:05,361 Hussain: you can be like, okay, these are the key points that we need to consider. 431 00:31:06,021 --> 00:31:09,001 Suzy: Cause I think, you know, that there's a, the last thing we want to do on this 432 00:31:09,001 --> 00:31:12,321 Suzy: show is create any form of moral panic. We want to actually put people back 433 00:31:12,321 --> 00:31:15,821 Suzy: in control and say, well, actually, okay, here is this situation and it's coming 434 00:31:15,821 --> 00:31:18,901 Suzy: our way, whether we like it or not, but actually here's what we can do about it. 435 00:31:18,981 --> 00:31:21,901 Suzy: This is what's within our, what do they call it? The locus of control. 436 00:31:22,221 --> 00:31:22,541 Hussain: Yeah. 437 00:31:23,266 --> 00:31:26,906 Hussain: And it's a potential opportunity. Yes, there's a threat. 438 00:31:27,226 --> 00:31:31,686 Hussain: Absolutely, there is a threat that this will just be overly relied on and considered 439 00:31:31,686 --> 00:31:37,866 Hussain: sort of a more effective way to improve the weight of a population rather than 440 00:31:37,866 --> 00:31:39,606 Hussain: through lifestyle intervention. 441 00:31:39,866 --> 00:31:44,026 Hussain: Or we could say, look, this is actually an opportunity to embed proper lifestyle 442 00:31:44,026 --> 00:31:48,606 Hussain: medicine within primary care because for so many people, it's in their interest. 443 00:31:48,726 --> 00:31:49,946 Hussain: It's in the interest of the patient. 444 00:31:50,146 --> 00:31:54,186 Hussain: It's in the interest of the commissioners. It's in the interest of also primary 445 00:31:54,186 --> 00:31:57,786 Hussain: care because we don't want to have to have patients constantly coming back and 446 00:31:57,786 --> 00:32:00,286 Hussain: maintaining them on lifelong treatments. 447 00:32:00,806 --> 00:32:05,906 Hussain: So apart from the pharmaceutical company, this is in the interest of everyone involved. 448 00:32:06,126 --> 00:32:11,346 Callum: The other thing that strikes me, the opportunity is that if people are losing weight, 449 00:32:11,466 --> 00:32:15,946 Callum: they've probably been wanting to do it for years and they probably get an emotional 450 00:32:15,946 --> 00:32:20,986 Callum: boost from the fact that they are being successful and that kind of wave of 451 00:32:20,986 --> 00:32:24,626 Callum: that offers a real opportunity to try and embed some of these other things like 452 00:32:24,626 --> 00:32:28,086 Callum: being more active and eating better. 453 00:32:28,466 --> 00:32:33,626 Hussain: Yeah and we know that when we compare in terms of when to start GLP-1s those 454 00:32:33,626 --> 00:32:38,546 Hussain: that have already lost five percent at least of weight through lifestyle interventions 455 00:32:38,546 --> 00:32:43,226 Hussain: do better and lose more weight on the GLP-1s compared to those that are going 456 00:32:43,226 --> 00:32:44,966 Hussain: from a cold start, so to speak. 457 00:32:46,166 --> 00:32:49,466 Callum: There's been so much gold in this from you, Hussein, which has been awesome. 458 00:32:49,726 --> 00:32:53,566 Callum: I suspect we're 30 odd minutes in and it's going to be a double listen, 459 00:32:53,866 --> 00:32:56,166 Callum: probably for me anyway, to take notes. 460 00:32:56,706 --> 00:33:01,546 Callum: But I wondered, Susie, I'm going to put you on the spot. You mentioned the jigsaw. 461 00:33:02,126 --> 00:33:06,766 Callum: Talk to me, visualize that jigsaw for us and then maybe Hussein can add any 462 00:33:06,766 --> 00:33:11,466 Callum: other pieces to that jigsaw and that can be our kind of conclusion to the episode? 463 00:33:11,706 --> 00:33:14,486 Suzy: I guess for me with a jigsaw I tend to base 464 00:33:14,486 --> 00:33:18,046 Suzy: it around the pillars of lifestyle medicine and I'll 465 00:33:18,046 --> 00:33:20,746 Suzy: just loosely put them in but I will tailor that to the patient in 466 00:33:20,746 --> 00:33:24,246 Suzy: front of me and I'll say well listen of all of these ones that I've briefly mentioned which 467 00:33:24,246 --> 00:33:27,006 Suzy: is the most important one to you because usually when you access one you're 468 00:33:27,006 --> 00:33:29,726 Suzy: going to start having a ripple effect on all of 469 00:33:29,726 --> 00:33:32,846 Suzy: the other ones so I would start with the bare bones sometimes 470 00:33:32,846 --> 00:33:35,526 Suzy: if I haven't got time I'll actually just give it to them and say listen this is for you 471 00:33:35,526 --> 00:33:38,446 Suzy: to work on when you go home you didn't realize you're going to get homework from me 472 00:33:38,446 --> 00:33:41,526 Suzy: there is a schoolteacher inside me um if 473 00:33:41,526 --> 00:33:44,206 Suzy: I had longer you know there's there's so many things I don't even 474 00:33:44,206 --> 00:33:47,066 Suzy: know which one to pick up on but I just I loved what you're saying there he's 475 00:33:47,066 --> 00:33:50,986 Suzy: saying about actually in terms of adherence because that's a major problem with 476 00:33:50,986 --> 00:33:54,806 Suzy: it actually if you if you're aware that you can take control of that and and 477 00:33:54,806 --> 00:33:58,146 Suzy: make changes like you know increasing your fiber and your water intake and that's 478 00:33:58,146 --> 00:34:02,546 Suzy: going to stop you from being as constipated you know then that's that's that's 479 00:34:02,546 --> 00:34:03,966 Suzy: a really good starting point so, 480 00:34:04,726 --> 00:34:08,926 Suzy: doing the simple things well, which is what I start most of my talks about lifestyle medicine with. 481 00:34:10,150 --> 00:34:15,990 Hussain: Absolutely. And I think, I think you use the, these injections and the benefit 482 00:34:15,990 --> 00:34:21,810 Hussain: they give them as Callum rightly said, in that it can give them that motivation that it's fine. 483 00:34:21,990 --> 00:34:26,250 Hussain: Things are finally working and what you need to instill and what you need to 484 00:34:26,250 --> 00:34:31,430 Hussain: get right from the beginning of this process is that this is a temporary effect. 485 00:34:31,550 --> 00:34:33,470 Hussain: It doesn't leave permanent impact. 486 00:34:33,710 --> 00:34:37,510 Hussain: So you need to start working on those pillars of lifestyle medicine for when 487 00:34:37,510 --> 00:34:41,570 Hussain: this injection is stopped, what are you going to lean on? 488 00:34:41,890 --> 00:34:45,610 Hussain: You know, is your sleep still going to be really poor? Is there going to be 489 00:34:45,610 --> 00:34:50,890 Hussain: still a high amount of stress, which drives you to have an unhealthy relationship with food? 490 00:34:51,010 --> 00:34:54,810 Hussain: You know, do you, have you considered how you're going to alter your, 491 00:34:54,810 --> 00:34:58,850 Hussain: your portion sizes and the kind of foods that you eat, et cetera. 492 00:34:59,050 --> 00:35:03,850 Hussain: So it's kind of like a window of time where a lot of work can be done. 493 00:35:04,170 --> 00:35:07,950 Hussain: And we're always thinking and planning about the end day. You know, 494 00:35:08,070 --> 00:35:10,790 Hussain: what is the end day of these medications and what is the plan after that? 495 00:35:11,150 --> 00:35:16,590 Hussain: Because I think most people don't want to just lose weight. They want to maintain on that weight loss. 496 00:35:17,490 --> 00:35:22,130 Hussain: And so it's going to be so important for GPs with an extended role in lifestyle 497 00:35:22,130 --> 00:35:27,030 Hussain: medicine to be the kind of leaders within the clusters, networks, 498 00:35:27,230 --> 00:35:28,930 Hussain: to be able to support patients in that. 499 00:35:29,050 --> 00:35:34,330 Hussain: Because unfortunately, and actually NICE, very much clearly documented this in their notes. 500 00:35:34,730 --> 00:35:38,950 Hussain: In primary care, it's very patchy in terms of the lifestyle support patients can get. 501 00:35:39,250 --> 00:35:43,230 Hussain: Interestingly, the drug company said that they did a survey and nearly all the 502 00:35:43,230 --> 00:35:46,530 Hussain: GPs said that there was loads of lifestyle support within primary care, 503 00:35:46,810 --> 00:35:50,890 Hussain: which NICE luckily didn't quite believe, and I don't think anyone would. 504 00:35:51,570 --> 00:35:56,430 Hussain: So yeah, what I'm hopeful for is that we can, in that pillar approach, 505 00:35:56,490 --> 00:35:59,810 Hussain: I think is absolutely important because pretty much every pillar is associated 506 00:35:59,810 --> 00:36:02,450 Hussain: in some way with obesity. 507 00:36:03,350 --> 00:36:05,250 Hussain: All of those are important. 508 00:36:06,170 --> 00:36:09,430 Hussain: And when we think about looking at the studies, yes, physical activity, 509 00:36:09,630 --> 00:36:12,930 Hussain: strength training seems to be really important. Protein, yeah, that's important. 510 00:36:13,510 --> 00:36:17,890 Hussain: They're kind of the things that have been tested. It's very hard to test improvements 511 00:36:17,890 --> 00:36:21,030 Hussain: in sleep. It's very hard to test improvements in relationships, 512 00:36:21,390 --> 00:36:22,350 Hussain: improvements in stress. 513 00:36:22,850 --> 00:36:28,350 Hussain: But we know anecdotally, and when we're supporting patients, they have a huge impact. 514 00:36:28,610 --> 00:36:31,770 Hussain: They have a huge impact. And obesity is a long-term condition, 515 00:36:32,010 --> 00:36:34,270 Hussain: just like all of the other ones that we manage. 516 00:36:34,850 --> 00:36:39,470 Hussain: And an injection, a medication is never going to be the answer because it wasn't the problem. 517 00:36:40,930 --> 00:36:45,050 Hussain: Patients didn't have a GLP-1 deficiency. That isn't the disease. 518 00:36:45,190 --> 00:36:49,130 Hussain: If that was the disease, then fine. This is the solution, but it's not. 519 00:36:49,650 --> 00:36:53,410 Hussain: Instead, we're trying to work on the physiology that we understand to buy patient 520 00:36:53,410 --> 00:37:00,210 Hussain: support in trying to get the body to a lower weight because we know that it doesn't like to do that. 521 00:37:00,370 --> 00:37:03,870 Hussain: And it's got lots of fail-safe mechanisms to stop you losing weight and to make 522 00:37:03,870 --> 00:37:06,050 Hussain: it really hard to lose the weight. 523 00:37:07,544 --> 00:37:12,004 Hussain: The biggest concern I've got is not that lifestyle won't be implemented along these injections, 524 00:37:12,524 --> 00:37:18,124 Hussain: is that we are not going to do any work in the environment because that, in fact, 525 00:37:18,324 --> 00:37:22,544 Hussain: is what's meaning that people have to have such a scaffolding around their life 526 00:37:22,544 --> 00:37:29,604 Hussain: in terms of protective behaviors and ways to manage their life that it's unmanageable 527 00:37:29,604 --> 00:37:31,064 Hussain: for many to achieve that. 528 00:37:31,264 --> 00:37:34,344 Hussain: For sure, you know, like many of us are lucky. Maybe we have enough time. 529 00:37:34,344 --> 00:37:37,304 Hussain: We have enough motivation. We have enough support. we have 530 00:37:37,304 --> 00:37:40,104 Hussain: enough finances to make it doable to lead a healthy 531 00:37:40,104 --> 00:37:42,904 Hussain: lifestyle but for others the environment they 532 00:37:42,904 --> 00:37:47,124 Hussain: live in means that the amount of work and finances they'd have to implement 533 00:37:47,124 --> 00:37:52,564 Hussain: to achieve it it's just unmanageable and so i worry that it's the environment 534 00:37:52,564 --> 00:37:56,484 Hussain: and making changes to that that's going to be left behind rather than even the 535 00:37:56,484 --> 00:38:00,144 Hussain: lifestyle support within healthcare i think that's probably just about doable 536 00:38:00,144 --> 00:38:02,484 Hussain: if we knock on the right doors yeah. 537 00:38:02,484 --> 00:38:06,384 Callum: I think that's a really key point and um one that we've highlighted across a 538 00:38:06,384 --> 00:38:11,384 Callum: few podcasts now is is is the role of the environment and uh or the importance 539 00:38:11,384 --> 00:38:15,324 Callum: of the environment and the role of the health professional and others in advocacy 540 00:38:15,324 --> 00:38:20,904 Callum: to try and make a change there and uh yeah i i think that's really key. 541 00:38:20,904 --> 00:38:27,024 Hussain: And i i wonder whether when we think about our role whether we're clinicians 542 00:38:27,024 --> 00:38:29,544 Hussain: whether we're coming from the physical activity sector. 543 00:38:29,884 --> 00:38:36,844 Hussain: And I wonder if what we need to consider is focus on the economic argument of this, 544 00:38:36,984 --> 00:38:41,284 Hussain: because often it's the economic argument that gets sold really well as to why 545 00:38:41,284 --> 00:38:45,764 Hussain: we shouldn't change the environment as it is, because it generates X, Y, Z. 546 00:38:46,604 --> 00:38:52,204 Hussain: But I think more and more now we're starting to realize that the biggest inhibitor 547 00:38:52,204 --> 00:38:54,184 Hussain: to economic growth is poor health. 548 00:38:54,524 --> 00:38:59,544 Hussain: And it's taken a humongous list of patients that are off long-term sick for 549 00:38:59,544 --> 00:39:02,044 Hussain: people to start to want to tackle that. 550 00:39:02,444 --> 00:39:07,344 Hussain: And that gets tackled not by trying to inject these people back into work. 551 00:39:07,344 --> 00:39:11,504 Hussain: That gets tackled by understanding what was the environment that led to. 552 00:39:12,683 --> 00:39:19,183 Hussain: The largest number of people within the working age being too unwell to work. 553 00:39:19,343 --> 00:39:21,303 Hussain: And it's just really upsetting. 554 00:39:21,503 --> 00:39:25,703 Hussain: You know, it's really upsetting. We've actually launched a lifestyle group consultations 555 00:39:25,703 --> 00:39:30,143 Hussain: for patients that have been off work for three months or more through the ICB, 556 00:39:30,283 --> 00:39:31,543 Hussain: through like a work well project. 557 00:39:32,083 --> 00:39:35,923 Hussain: And I'll be honest, I had some really bad biases. I thought no one's coming 558 00:39:35,923 --> 00:39:38,123 Hussain: to this. You know, I'm going to send out this text to patients. 559 00:39:38,443 --> 00:39:41,823 Hussain: None of these patients want to come and get support on lifestyle. 560 00:39:42,403 --> 00:39:43,663 Hussain: But hell, they're paying me, 561 00:39:43,803 --> 00:39:48,203 Hussain: so I'm going to do it. Now, I can just literally see on my computer, Dr. 562 00:39:48,343 --> 00:39:53,423 Hussain: Fleming, he's one of my colleagues, Joe Fleming, the clinic is inundated. 563 00:39:53,763 --> 00:39:57,643 Hussain: She's like, I'm scared now to open the other practices because I know that we're 564 00:39:57,643 --> 00:40:02,383 Hussain: going to have way too many patients than we can even consider dealing with in the next six months. 565 00:40:03,363 --> 00:40:06,423 Hussain: And so I think that tells you that these people, they're not work shy. 566 00:40:09,163 --> 00:40:13,103 Hussain: They They're actually, unfortunately, living in such an environment that they 567 00:40:13,103 --> 00:40:17,123 Hussain: find it exceptionally difficult to maintain work. 568 00:40:17,343 --> 00:40:20,483 Hussain: And that's the biggest disappointment, I think, in all of this, 569 00:40:20,583 --> 00:40:23,163 Hussain: that we've created an environment that causes that much illness. 570 00:40:24,423 --> 00:40:27,963 Callum: We need to get you on and respond to Wes Streeting. 571 00:40:29,783 --> 00:40:35,643 Hussain: Absolutely. He can come to the clinic anytime. He can come down and speak to them himself. 572 00:40:36,843 --> 00:40:39,863 Callum: All right well look that uh that's been really 573 00:40:39,863 --> 00:40:42,703 Callum: great from my personal perspective and hopefully for 574 00:40:42,703 --> 00:40:47,003 Callum: everyone listening as well uh as ever we'd love to hear your feedback and and 575 00:40:47,003 --> 00:40:51,423 Callum: if you want to be on the podcast let us know uh i'm gonna leave the final word 576 00:40:51,423 --> 00:40:56,443 Callum: with you hussein just like maybe two key take homes and you really just want 577 00:40:56,443 --> 00:41:01,123 Callum: to really hit home before uh before we we head into whatever we're doing you. 578 00:41:01,123 --> 00:41:05,283 Hussain: Know what rather than take homes callum i'm gonna give action points because 579 00:41:05,283 --> 00:41:09,083 Hussain: I need people to support in this project. 580 00:41:09,083 --> 00:41:13,023 Hussain: So for healthcare professionals listening to this that have a lifestyle, 581 00:41:13,863 --> 00:41:17,243 Hussain: either qualification or background or interest. 582 00:41:18,741 --> 00:41:23,201 Hussain: Speak to your partners, speak to the head of your clusters, say that you would 583 00:41:23,201 --> 00:41:28,161 Hussain: be happy to support the rollout of these medications when it comes and when it's properly funded. 584 00:41:28,701 --> 00:41:33,941 Hussain: And that it's super important that a wraparound lifestyle medicine support is 585 00:41:33,941 --> 00:41:36,321 Hussain: offered to these patients. So that's the part that you need to do. 586 00:41:36,521 --> 00:41:39,441 Hussain: Anyone from the physical activity sector that's listening to this, 587 00:41:39,601 --> 00:41:44,361 Hussain: this is probably your best opportunity to integrate into health. 588 00:41:44,681 --> 00:41:48,941 Hussain: Because And of all the things that we are going to consider, 589 00:41:49,941 --> 00:41:54,361 Hussain: NICE are very much going to push physical activity because it's got the biggest 590 00:41:54,361 --> 00:41:56,101 Hussain: evidence base for improving this. 591 00:41:56,281 --> 00:42:01,641 Hussain: So this is your chance to support these kind of patients directly through healthcare 592 00:42:01,641 --> 00:42:05,721 Hussain: and you can build up those relationships and think about how that will trickle beyond obesity. 593 00:42:05,721 --> 00:42:09,661 Hussain: You know, once you develop these relationships and these pathways and we can 594 00:42:09,661 --> 00:42:14,621 Hussain: break down the barriers that we get on activity for referral and all those kinds of elements, 595 00:42:14,621 --> 00:42:17,341 Hussain: we can hopefully start to see a 596 00:42:17,341 --> 00:42:21,621 Hussain: world where other long-term conditions are managed in the same way, okay? 597 00:42:21,881 --> 00:42:25,321 Hussain: In the same way, rather than just specific rehabs that they have to go with 598 00:42:25,321 --> 00:42:30,341 Hussain: long waiting lists that we can consider always as a packaged approach rather 599 00:42:30,341 --> 00:42:34,661 Hussain: than a troubleshoot approach that we have often with long-term conditions. 600 00:42:34,661 --> 00:42:39,041 Hussain: So yeah that's my big ask that people go out try to latch on to this opportunity 601 00:42:39,041 --> 00:42:42,561 Hussain: and let's make sure that it's delivered correctly amazing. 602 00:42:42,561 --> 00:42:46,161 Callum: Well thanks thanks Hussain thanks Susie lovely chat. 603 00:42:46,161 --> 00:42:48,041 Hussain: Thank you I. 604 00:42:48,041 --> 00:42:50,441 Suzy: Love those call to actions there well done Hussain.